[8-K] SANGAMO THERAPEUTICS, INC Reports Material Event

Sangamo Therapeutics, Inc. reported a preliminary estimate that its cash and cash equivalents were approximately $20.9 million as of December 31, 2025.

Rhea-AI Filing Summary

Sangamo Therapeutics, Inc. reported a preliminary estimate that its cash and cash equivalents were approximately $20.9 million as of December 31, 2025. This figure is unaudited, subject to change, and may be adjusted when the audited financial statements for 2025 are completed.

The company also disclosed a leadership change in its finance team. On February 2, 2026, the employment of Prathyusha Duraibabu, the principal financial officer, terminated. Effective February 3, 2026, Nikunj Jain, Vice President, Finance and Corporate Controller and principal accounting officer, was appointed Interim Chief Financial Officer and will serve as the principal financial officer without additional compensation.

Insights

Biotech equity analyst

Sangamo reports low preliminary cash balance and replaces its principal financial officer with an internal interim CFO.

Sangamo Therapeutics provides a preliminary, unaudited cash and cash equivalents estimate of $20.9 million as of December 31, 2025. The company notes this figure may change once its 2025 audit is completed and explicitly warns that any adjustments could be material.

Separately, the employment of principal financial officer Prathyusha Duraibabu terminated on February 2, 2026. On February 3, 2026, Nikunj Jain, already serving as Vice President, Finance and Corporate Controller and principal accounting officer, was appointed Interim Chief Financial Officer and designated as the new principal financial officer, with no additional compensation.

The leadership change concentrates key finance responsibilities in an existing senior finance executive, which may support continuity but also underscores the importance of upcoming audited results for the year ended December 31, 2025. Subsequent company filings are expected to provide the full audited financials and any revisions to the $20.9 million cash estimate.

8-K Event Classification

2 items: 2.02, 5.02

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cash balance did Sangamo Therapeutics (SGMO) report as of December 31, 2025?

Sangamo Therapeutics estimated its cash and cash equivalents at approximately $20.9 million as of December 31, 2025. This figure is preliminary, unaudited, and may change once the company completes its audited financial statements for the 2025 fiscal year.

Is Sangamo Therapeutics’ reported $20.9 million cash balance audited?

No, the approximately $20.9 million cash and cash equivalents balance is a preliminary, unaudited estimate. Sangamo states that the amount is subject to change following completion of its audit for the year ended December 31, 2025, and any adjustments could be material.

What leadership change in the finance team did Sangamo Therapeutics (SGMO) disclose?

Sangamo disclosed that the employment of its principal financial officer, Prathyusha Duraibabu, terminated on February 2, 2026. The company then appointed Nikunj Jain as Interim Chief Financial Officer and principal financial officer effective February 3, 2026.

Who is Sangamo Therapeutics’ Interim Chief Financial Officer and principal financial officer?

Nikunj Jain, previously Vice President, Finance and Corporate Controller and principal accounting officer, was appointed Interim Chief Financial Officer and will serve as Sangamo’s principal financial officer effective February 3, 2026, following the termination of Prathyusha Duraibabu’s employment.

Will Sangamo Therapeutics’ Interim CFO receive additional compensation for the role?

No. Sangamo states that Nikunj Jain will not receive any additional compensation in connection with his appointment as Interim Chief Financial Officer. His compensation arrangements remain those previously described in the company’s September 2025 filing, which is incorporated by reference.

Is the preliminary cash information in Sangamo’s 8-K considered filed financial information?

No. Sangamo specifies that the information under Item 2.02, including the $20.9 million cash estimate, is not deemed “filed” for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, limiting associated statutory liabilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 08:55 AM Learn about SEC filing dates

0001001233false00010012332026-02-022026-02-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2026

 SANGAMO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

  

Delaware

000-30171

68-0359556

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer ID Number)

501 Canal Blvd., Richmond, California 94804

(Address of principal executive offices) (Zip Code)

(510) 970-6000

(Registrant’s telephone number, including area code) 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report) 

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value per share

SGMO

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition.

On February 3, 2026, Sangamo Therapeutics, Inc. announced its preliminary estimate that its cash and cash equivalents as of December 31, 2025 were approximately $20.9 million.

The information in this Item 2.02 is preliminary, has not been audited and is subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2025. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025.

The information in this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 2, 2026, the employment of Prathyusha Duraibabu, the Company’s principal financial officer, terminated. Effective February 3, 2026, Nikunj Jain, Sangamo’s Vice President, Finance and Corporate Controller and principal accounting officer, has been appointed to the position of Interim Chief Financial Officer and will serve as the Company’s principal financial officer.

Biographical information for Mr. Jain can be found in the Company’s Current Report on Form 8-K filed on September 30, 2025 (the “September 2025 Form 8-K”) and is incorporated by reference herein.

There is no arrangement or understanding between Mr. Jain and any other person pursuant to which Mr. Jain was appointed as Interim Chief Financial Officer of the Company, and there are no family relationships between Mr. Jain and any of the Company’s directors or executive officers. Mr. Jain has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Mr. Jain will not receive any additional compensation in connection with his appointment as Interim Chief Financial Officer. Mr. Jain’s compensation arrangements are described in the September 2025 Form 8-K and incorporated by reference herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SANGAMO THERAPEUTICS, INC.

Dated: February 3, 2026

By:

/s/ SCOTT B. WILLOUGHBY

Name:

Scott B. Willoughby

Title:

Chief Legal Officer and Corporate Secretary